SCHEMBL4144820

SCHEMBL4144820

COC(=O)CNC(=O)N(C)c1ccc(SC(F)(F)F)cc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRZ1 P23471 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
MCHR1 Q99705 1/20 0.34
EPHX2 P34913 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
KCNK2 O95069 3/20 0.33
KCNK10 P57789 2/20 0.33
KDM4E B2RXH2 2/20 0.33
GAA P10253 2/20 0.33
ABCB1 P08183 1/20 0.33
ABCC1 P33527 1/20 0.33
MAPT P10636 2/20 0.32
GPBAR1 Q8TDU6 1/20 0.32
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
PIK3C3 Q8NEB9 1/20 0.32
RXFP1 Q9HBX9 1/20 0.31
STAMBP O95630 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4142022 0.86 PTPRZ1 (0.37) PTPRZ1SMN1; SMN2MCHR1EPHX2NR1H4
SCHEMBL13774526 0.86 MCHR1 (0.37) PTPRZ1SMN1; SMN2MCHR1EPHX2NR1H4
SCHEMBL4150851 0.85 PTPRZ1 (0.36) PTPRZ1MCHR1EPHX2NR1H4KCNK2
SCHEMBL4145099 0.85 KMT2A (0.34) PTPRZ1MCHR1EPHX2NR1H4KCNK2
SCHEMBL4158539 0.84 MAPT (0.36) PTPRZ1MCHR1EPHX2NR1H4KCNK2
SCHEMBL4149940 0.83 PTPRZ1 (0.35) PTPRZ1MCHR1EPHX2NR1H4KCNK2
SCHEMBL4149965 0.83 ACKR3 (0.38) PTPRZ1SMN1; SMN2MCHR1EPHX2NR1H4
SCHEMBL4155698 0.82 PTPRZ1 (0.44) PTPRZ1EPHX2NR1H4GAAHTT
SCHEMBL4146959 0.82 L3MBTL1 (0.35) PTPRZ1MCHR1EPHX2NR1H4KDM4E
SCHEMBL4150001 0.82 MAPK1 (0.35) PTPRZ1SMN1; SMN2MCHR1EPHX2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176786-A1 Benzoylurea Compounds and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-07-09 US disclosed
US-20090176786-A1 Benzoylurea Compounds and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-07-09 US disclosed
US-20090176786-A1 Benzoylurea Compounds and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-07-09 US disclosed
EP-1937629-A2 BENZOYLUREA COMPOUNDS AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-07-02 EP disclosed
WO-2007046513-A2 BENZOYLUREA COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176786-A1 Benzoylurea Compounds and Use Thereof BTK, BRIX1, NFXL1 PTPRZ1 1175/4885SMN1; SMN2 2011/4885MCHR1 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.